Skip to main content
European Commission logo print header

Mycobacteriophages to treat tuberculosis - Passed station or future promise?

Projektbeschreibung

Tuberkulosebehandlung mit Bakteriophagen

Bakteriophagen sind Viren, die Bakterien infizieren und abtöten. Die wachsende Bedrohung durch Arzneimittelresistenzen hat erneut das Interesse an dieser Behandlungsoption geweckt. Das im Rahmen der Marie-Skłodowska-Curie-Maßnahmen finanzierte Projekt Phage-TB zielt darauf ab, klinische Mykobakteriophagen zur Bekämpfung von Tuberkulose und nicht-tuberkulösen Mykobakterien zu entwickeln. Die DNS von aus dem Boden isolierten Mykobakteriophagen wird sequenziert, um vielversprechende Mykobakteriophagen mit lytischer Wirkung gegen Tuberkulose oder Infektionen mit nicht-tuberkulösen Mykobakterien auszuwählen. Die Phagencocktails werden für klinische Behandlungszwecke im Sinne der Inhalationsmethode optimiert, wobei die Phagen intakt und funktionsfähig bleiben. Der ausgewählte Mykobakteriophagen-Cocktail gegen Tuberkulose wird in einer ersten klinischen Studie am Menschen eingesetzt, um Sicherheit, Dosierung und Wirksamkeit zu bewerten.

Ziel

The emergence of drug-resistance to tuberculosis (TB) drugs poses an increasing challenge to TB control and new treatment options are urgently needed. Novel or repurposed antibiotics are still being introduced, but this pipeline will dry out in the near future.
Bacteriophages are viruses that kill bacteria. They have been used to treat infections before the introduction of antibiotics. With the emergence of drug-resistance there is renewed interest in this ancient treatment option. Clinical use of mycobacteriophages to treat TB and non-tuberculous mycobacterial (NTM) infections is still in its infancy.
This project contributes to 3 areas in the development of clinically useful mycobacteriophage treatments for TB and NTM infections:
- Phage discovery: From soil samples collected in the compounds of TB clinics and hospitals in Cape Town, South Africa, we will isolate mycobacteriophages using spot tests and plaque assays. DNA of newly discovered mycobacteriophages will be sequenced and during the return phase of this project I will select promising mycobacteriophages with lytic effect against TB or NTM infections, that can be used for development of phage cocktails for clinical use.
- Phage inhalation method: the efficiency of phage treatment is dependent upon the phage concentration reached at the site of disease. Phages that can attack M tuberculosis have long tails which might be vulnerable to manipulation. We will optimize an inhalation method leaving the phages intact and functional.
- Preparation for a clinical trial: an existing mycobacteriophage cocktail active against TB will be used for a first clinical study in humans to assess dosing, safety and efficiency.
If our mycobacteriophage hunt is successful, and the translation can be made into purified and adequately dosed administration of mycobacteriophages, a virtually inexhaustible addition will be made to the therapeutic armamentarium for drug-resistant as well as drug-sensitive TB and NTM infections.

æ

Koordinator

STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRUM
Netto-EU-Beitrag
€ 238 993,92
Adresse
Geert grooteplein 10 zuid
6525 GA Nijmegen
Niederlande

Auf der Karte ansehen

Region
Oost-Nederland Gelderland Arnhem/Nijmegen
Aktivitätstyp
Higher or Secondary Education Establishments
Links
EU-Beitrag
Keine Daten

Partner (2)